Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

This study aimed to compare serum CST levels between OLP patients and healthy controls and to examine their association with clinical subtype, disease severity, and vitamin D status.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Methods: In this cross-sectional study, 51 patients with clinically and histopathologically confirmed OLP and 60 healthy controls were enrolled at the University Hospital of Split.

Source: Abstract.

Seventy-three patients were screened; 22 were excluded because at least one inclusion or exclusion criterion was not met.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Serum Catestatin Level as a Novel Biomarker of Oral Lichen Planus

Cross-sectional study · Medical Sciences · 2026

Original publication title

Serum Catestatin Level as a Novel Biomarker of Oral Lichen Planus

Mia Roglic Karan; Dinko Martinovic; Ema Puizina; Lovre Martinovic; Jasna Puizina; Daniela Supe-Domic; Roko Santic; Josko Bozic; Livia Sukanec

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In this study, serum CST concentrations were increased in patients with OLP and correlated with REU total score, pain and burning. The most clinically informative finding was the higher CST concentration in erosive OLP, whereas non-erosive OLP showed CST values closer to controls. These results suggest that CST may be involved in the neuroendocrine-immune profile of OLP and may be more relevant as a marker of erosive or clinically active disease than as a general diagnostic marker for all OLP.

Confirmation in larger prospective cohorts, ideally with salivary measurements and tissue-level CST/CgA expression, is required before CST can be proposed for routine disease monitoring.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Oral lichen planus (OLP) is a chronic immune-mediated disorder of the oral mucosa, estimated to affect roughly 0.5% to 2% of the population and observed most often in middle-aged women [1]. Clinically, OLP can appear as reticular, atrophic, erosive, plaque-like, papular or bullous lesions, with relapsing and remitting symptoms that often require long-term follow-up [2]. Its etiology has not been fully resolved, but epithelial injury is considered to be driven primarily by cytotoxic T-cell responses, together with genetic susceptibility, psychological stress, viral triggers, and systemic autoimmune influences [3].

Because OLP is classified by the World Health Organization as an oral potentially malignant disorder, surveillance remains important; published malignant transformation estimates approach 1.5% in some series [4].

Catestatin (CST) is a 21-amino-acid peptide (hCgA352-372) produced by proteolytic processing of chromogranin A (CgA), a secretory granule protein released with catecholamines from adrenal chromaffin cells and other neuroendocrine tissues [5]. Originally described as an inhibitor of nicotinic cholinergic catecholamine release, CST is now recognized as a multifunctional peptide involved in cardiovascular regulation, antimicrobial defense, metabolic control, and innate immune signaling [6,7,8]. In inflammation, CST promotes a shift from classically activated M1 macrophages toward an M2-like phenotype, decreases TNF-alpha, IL-1beta and IL-6 production, restrains leukocyte recruitment, and down-regulates endothelial adhesion molecules [9,10].

Altered circulating CST concentrations have been described in rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis and COVID-19, supporting its relevance as a systemic marker of inflammatory activity [5,6,7,8,10].

Although OLP manifests locally in the oral mucosa, its inflammatory microenvironment is influenced by systemic neuroendocrine and immune inputs. Psychological stress, a commonly reported disease modifier, activates the hypothalamic: pituitary: adrenal axis and the sympathoadrenal system, which promote catecholamine and CgA release [11,12]. Because CgA is the precursor of CST, changes in sympathoadrenal signaling could alter CST availability in parallel with OLP activity. More importantly, systemic CST can interact with pathways that are directly relevant to oral mucosal inflammation, including endothelial adhesion molecule expression, chemokine-driven leukocyte trafficking, macrophage polarization, and T-cell-dominated epithelial damage [10,13,14,15].

These mechanisms provide a biologically plausible bridge between a circulating neuroendocrine-derived peptide and the local homing and activation of lymphocytes in OLP lesions. Previous studies have examined biomarkers such as angiopoietin-2, vitamin D, immunoglobulins and salivary cortisol in OLP, but serum catestatin has not yet been specifically evaluated [16,17].

Accordingly, this study measured serum CST levels in patients with OLP and healthy controls. We also examined whether CST concentrations differ by erosive status and whether they correlate with REU-based disease activity, symptom intensity, and vitamin D concentrations.

Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction

Study methods

What methods does the paper describe?

2.1. Study Design and Ethical Considerations

This cross-sectional study was carried out at the Department of Oral Pathology, University Hospital of Split, between April 2023 and November 2025.

The protocol was approved by the Ethics Committee of the University Hospital of Split (No. 2181-147/01/06/LJ.Z.-23-03; 14 March 2023). The study followed the Declaration of Helsinki, and all participants received study information before providing written informed consent.

2.2. Subjects

Patients with OLP were recruited from the Department of Oral Pathology, University Hospital of Split. Participation was voluntary and anonymized, and all patients received standard clinical care. Seventy-three patients were screened; 22 were excluded because at least one inclusion or exclusion criterion was not met. Medication history was recorded at enrollment, and blood was drawn before any new OLP-directed topical or systemic treatment was initiated.

Controls were healthy volunteers attending routine dental/oral check-ups at the same institution. They had no oral mucosal lesions and no history or clinical evidence of oral inflammatory, autoimmune, potentially malignant, or malignant disease. The same exclusion criteria applied to controls and OLP patients. Current smoking was defined as any active cigarette use within the previous 30 days. Everyday alcohol consumption was recorded as daily intake of alcoholic beverages.

Inclusion criteria were age 18 to 70 years and a diagnosis of OLP.

Exclusion criteria were active malignancy; chronic renal or hepatic disease; cardiovascular disease, including arterial hypertension and use of antihypertensive medication; diabetes mellitus; rheumatologic or autoimmune disease; oral vitamin D supplementation; psychoactive substance abuse; and current topical or systemic corticosteroid therapy or other OLP-directed immunomodulatory treatment at the time of sampling.

2.3. Laboratory and Clinical Examination

All participants underwent medical history review, physical examination, anthropometric measurements, and laboratory testing. OLP diagnosis was established using clinical and histopathological criteria according to the modified World Health Organization diagnostic framework summarized in recent diagnostic recommendations [3]. Potential controls with clinical or laboratory evidence of inflammation were excluded; C-reactive protein and leukocyte count were used as laboratory screening markers. Body height and weight were measured with a calibrated medical scale with an integrated stadiometer (Seca, Birmingham, UK), and BMI was calculated as weight in kilograms divided by height in meters squared.

After a 12-h overnight fast, venous blood was collected from the cubital vein. Routine laboratory testing was performed on the day of sampling, while serum aliquots intended for CST analysis were centrifuged and stored at −80 °C until assay. All analyses followed standard laboratory procedures and were performed by the same experienced biochemist, who was blinded to group allocation.

Serum CST concentrations were measured by enzyme-linked immunosorbent assay using a commercially available kit (EK-053-27CE EIA kit, Phoenix Pharmaceuticals Inc., Burlingame, CA, USA). The manufacturer’s stated assay sensitivity was 0.05 ng/mL, with a measurement range of 0.05 to 100 ng/mL. Intra-assay and inter-assay coefficients of variation were <10% and <15%, respectively. Because no universally accepted clinical reference interval for serum CST is available for this assay, CST values were analyzed as continuous variables and compared between study groups.

Serum 25-hydroxyvitamin D [25(OH)D] was quantified using Elecsys Vitamin D (Roche Diagnostics International Ltd., Rotkreuz, Switzerland), an electrochemiluminescence immunoassay (ECLIA). Results were expressed in nmol/L, and the analytical measuring range was 7.5 to 250 nmol/L. For interpretation, vitamin D deficiency was considered <50 nmol/L, insufficiency 50 to 74.9 nmol/L, and sufficiency ≥ 75 nmol/L; however, the present analysis used continuous vitamin D values because individual category counts were not available for all analyses.

2.4. Assessment of Disease Activity

Clinical activity was graded with the Reticulation/Keratosis, Erythema, Ulceration (REU) system, a semi-quantitative clinician-reported tool that scores OLP lesions at ten intraoral sites [18]. A single experienced oral medicine specialist performed all REU assessments while blinded to CST and vitamin D results, using a standardized scoring sheet. Because only one examiner carried out the clinical grading and no repeat-scoring session was built into the protocol, formal inter-examiner and intra-examiner reliability coefficients were not available. At each site, reticulation/keratosis was scored as absent/present, erythema was scored from 0 to 3 according to surface area, and ulceration was scored from 0 to 3 according to ulcer size.

The total REU score was calculated as (R × 1) + (E × 2) + (U × 3).

Patients were classified as erosive if at least one erosive/ulcerative lesion was present at any oral site, regardless of concomitant reticular, papular, plaque-like, atrophic, or bullous changes. The non-erosive group included patients without erosive/ulcerative lesions; this group could include reticular, papular, plaque-like, or atrophic lesions.

Pain and burning were recorded separately on two distinct 0 to 10 visual analog scales (VAS). Patients were asked to rate their average spontaneous symptoms during the preceding 7 days, rather than provoked symptoms during eating, swallowing, or toothbrushing. A score of 0 represented no pain/burning, and 10 represented the worst imaginable pain/burning.

2.5. Sample Size Analysis

Sample size was estimated from pilot data obtained in 10 OLP patients and 10 matched controls. Serum CST, the primary outcome, had a mean concentration of 10.42 ± 5.75 ng/mL in the OLP group and 5.11 ± 3.11 ng/mL in controls. Assuming type I error of 0.05 and 90% power, at least 17 participants were required in each group.

2.6. Statistical Analyses

Statistical analyses were performed in MedCalc (MedCalc Software, Ostend, Belgium, version 23.5.5). Continuous variables are shown as mean ± standard deviation or median with interquartile range, depending on distribution, while categorical variables are reported as N (%). Normality was assessed with the Kolmogorov: Smirnov test. Normally distributed variables were compared using the independent-samples t-test; non-normally distributed variables were analyzed with the Mann: Whitney U test. Categorical variables were compared using the chi-square test or Fisher’s exact test when appropriate. Associations between CST and clinical variables were tested with Pearson’s or Spearman’s correlation coefficients according to distribution.

Statistical significance was set at p < 0.05.

Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods

Discussion

The main observation of this study was that circulating CST was higher in OLP patients than in controls and that CST was closely related to REU-based disease activity. The association was particularly evident in erosive OLP, where CST concentrations were markedly higher than in the non-erosive subgroup. These findings suggest that CST is more likely to reflect clinically active or erosive mucosal inflammation than the mere presence of OLP, and they expand the concept of a neuroendocrine-immune interface in this disease.

Increased serum CST in OLP is best interpreted within the broader neuroimmune biology of chronic mucosal inflammation. CST is generated from CgA, which is co-released with catecholamines during physiological and psychological stress [19,20]. OLP lesions are dominated by activated CD4+ and CD8+ T cells, Th1/Th17 skewing, altered Treg activity, and cytokines such as TNF-alpha, IFN-gamma, IL-6 and IL-17 [21,22,23,24]. These local processes may be linked to the systemic CST pool through stress-related CgA release, inflammation-enhanced CgA processing, and CST-mediated modulation of macrophages and leukocyte trafficking.

Experimental and clinical data indicate that CST can reduce TNF-alpha, IL-1beta and IL-6, attenuate adhesion molecule expression, and limit immune cell chemotaxis [10,15]. In this framework, higher CST could represent a compensatory counter-regulatory response to sustained mucosal inflammation. Similar increases have been reported in several inflammatory or immune-mediated conditions, including inflammatory bowel disease, rheumatoid arthritis, severe COVID-19 and cardiovascular inflammatory states [6,7,8,25], whereas reduced levels have been reported in some metabolic and hypertensive phenotypes [26,27].

Thus, CST dysregulation appears to depend on disease context, inflammatory burden and neuroendocrine activation rather than following a single direction across all disorders. To our knowledge, this is one of the first studies to report elevated serum CST in OLP.

The correlation between CST and the REU total score further supports a relationship with clinical activity. REU scoring captures reticulation/keratosis, erythema and ulceration across multiple oral sites and has been shown to correlate with pain [18,28]. As lesions become erythematous or ulcerated, epithelial barrier disruption, cytokine release and immune-cell recruitment intensify. Such conditions may enhance CgA processing and CST release from neuroendocrine and immune-cell compartments. The parallel correlations with VAS pain and VAS burning indicate that CST also tracks patient-reported symptoms, although the overall median VAS scores were low (1 for pain and 2 for burning).

These low values may reflect the inclusion of patients with limited or chronic lesions and confirm that symptom intensity should be interpreted together with objective REU scores rather than in isolation. Previous OLP biomarker studies have shown that angiopoietin-2, immunoglobulins, vitamin D and cortisol vary with disease severity [16]. Our findings add CST to this biomarker landscape and suggest a neuroendocrine dimension of OLP activity.

The higher CST concentrations observed in erosive OLP provide the clearest clinical signal in this dataset. Erosive OLP is considered a more severe phenotype, characterized by epithelial breakdown, greater symptom burden, CD8+ cytotoxic T-cell infiltration, TNF-alpha activity and basement membrane damage [29,30]. In contrast, non-erosive patterns usually show a more preserved epithelial barrier [31,32]. Therefore, the similarity between control and non-erosive CST medians in the present study is important: it suggests that CST may not be a general diagnostic marker for all OLP, but rather a marker of inflammatory escalation, ulceration or erosive activity.

This interpretation is consistent with reports that vascular and humoral biomarkers, such as angiopoietin-2 and immunoglobulins, are higher in erosive disease [16]. However, because the non-erosive subgroup was small, this finding requires confirmation in a study powered for direct comparisons among controls, non-erosive OLP and erosive OLP.

Vitamin D was lower in the overall OLP group than in controls, in line with previous studies and meta-analytic data [33,34,35,36,37]. The mean vitamin D values in both controls and the non-erosive subgroup were within the insufficiency range, which helps explain why the control mean (53.4 nmol/L) was close to the non-erosive mean (55.1 nmol/L). In contrast, the erosive subgroup had lower levels, supporting a possible link between vitamin D status and more severe mucosal disease.

Vitamin D signaling through VDR influences keratinocytes, dendritic cells, macrophages and T cells, promotes Treg differentiation and constrains Th1/Th17 responses [38,39]. Reduced vitamin D/VDR activity could therefore contribute to persistence of the inflammatory loop in OLP [35,40,41]. The lack of correlation between CST and vitamin D suggests that these biomarkers may reflect different aspects of disease biology: CST may be more closely related to neuroendocrine and inflammatory activation, whereas vitamin D reflects a VDR-centered immunoregulatory axis.

Future studies should test whether vitamin D repletion changes CST levels or whether both markers add complementary information on disease activity.

Several limitations should be acknowledged. The cross-sectional design prevents causal inference, and residual confounding cannot be excluded. The study was single-center and the sample size, particularly for the non-erosive subgroup, was modest. Importantly, OLP is a localized mucosal disease, whereas CST was measured only in serum; salivary CST, lesional CgA/CST expression, immunohistochemistry and tissue transcriptomic analyses were not performed. Clinical grading was performed by one examiner and formal inter: and intra-examiner reliability coefficients were not available, which limits assessment of scoring reproducibility.

Finally, although active corticosteroid therapy, antihypertensive treatment and vitamin D supplementation were exclusion criteria, detailed prior medication washout intervals and vitamin D category counts were not available, so residual medication: or nutritional-status confounding remains possible.

Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion

Results

Overall, 111 participants were analyzed: 60 controls and 51 patients with OLP (Table 1). The groups did not differ significantly in age (p = 0.331), BMI (p = 0.479), sex (p = 0.197), smoking status (p = 0.826), or everyday alcohol consumption (p = 0.405). Unless otherwise indicated, values in parentheses represent either percentages for categorical variables or interquartile ranges for skewed continuous variables.

Reticular OLP was the most common clinical pattern (47/51, 92.2%), whereas papular, atrophic and bullous types were each recorded in one patient (2.0%) (Table 2). Because multiple lesion types and sites could coexist, erosive/ulcerative lesions were present in 35 patients (68.6%), and 16 patients (31.4%) were classified as non-erosive. The buccal mucosa was the most frequent site (92.2%), while the oral floor was least often involved (5.9%).

Serum vitamin D concentrations were lower in the OLP group than in controls (45.1 ± 17.8 vs. 53.4 ± 18.07 nmol/L, p < 0.001) (Figure 1). Based on commonly used thresholds, both mean values fall below the sufficiency cut-off of 75 nmol/L.

Median serum CST was higher in patients with OLP than in controls (13.8 [6.9 to 25.0] vs. 6.4 [5.5 to 7.6] ng/mL, p < 0.001) (Figure 2).

Within the OLP group, serum CST showed strong positive correlations with REU-E score (r = 0.748, p < 0.001), REU-U score (r = 0.770, p < 0.001), REU total score (r = 0.781, p < 0.001), VAS pain (r = 0.708, p < 0.001), and VAS burning (r = 0.729, p < 0.001) (Table 3). No other statistically significant correlations were observed.

Exploratory subtype analysis showed higher serum CST in erosive OLP than in non-erosive OLP (21.9 [11.8 to 39.4] vs. 7.7 [5.7 to 12.7] ng/mL, p < 0.001) (Figure 3). Descriptively, the non-erosive OLP median was close to the control median (7.7 vs. 6.4 ng/mL), suggesting that the overall OLP-control difference was mainly driven by the erosive subgroup.

Serum vitamin D levels were also lower in the erosive subgroup than in the non-erosive subgroup (40.4 ± 16.07 vs. 55.1 ± 17.1 nmol/L, p < 0.001) (Figure 4). The control mean (53.4 nmol/L) and the non-erosive OLP mean (55.1 nmol/L) both fell within the insufficiency range defined above.

Table 1

Comparison of sociodemographic data and habits between the study groups.

VariableStudy Sample
(N = 111)
Control Group
(N = 60)
OLP Group
(N = 51)
p
Age (years)63.0 (56.0 to 68.7)63.0 (57.0 to 66.5)65.0 (53.0 to 71.7)0.331 *
BMI (kg/m2)23.6 ± 2.423.4 ± 2.323.8 ± 2.50.479 *
Sex (N, %)
Male34 (30.6)22 (36.7)12 (23.5)0.197 †
Female77 (69.4)38 (63.3)39 (76.5)
Smoking (N, %)24 (21.6)12 (20.0)12 (23.5)0.826 *
Every day alcohol consumption (N, %)2 (1.8)0 (0)2 (3.9)0.405 *

All variables are presented as whole numbers (percentage), mean ± standard deviation or median (interquartile range). * Mann: Whitney U test. † Chi-square test or Fisher’s exact test.

Table 2

Clinical data of the OLP group.

VariableOLP Group
(N = 51)
Type of OLP * (N, %)
Reticular47 (92.2)
Papular1 (2.0)
Plaque-like10 (19.6)
Atrophic1 (2.0)
Erosive/ulcerative35 (68.6)
Bullous1 (2.0)
Exhibiting erosive/non-erosive subtypes (N, %)
Non-erosive16 (31.4)
Erosive35 (68.6)
Localization * (N, %)
Buccal mucosa47 (92.2)
Gingiva10 (19.6)
Dorsal tongue7 (13.7)
Lateral tongue6 (11.8)
Ventral tongue7 (13.7)
Palate5 (9.8)
Labial vestibulum5 (9.8)
Oral floor3 (5.9)
REU-R score2.0 (2.0 to 3.0)
REU-E score2.0 (0.0 to 5.7)
REU-U score2.0 (0 to 4.0)
REU total score6.0 (3.0 to 11.5)
VAS pain1.0 (0 to 4.0)
VAS burning2.0 (0 to 5.0)

All variables are presented as whole numbers (percentage) or median (interquartile range). * most patients had multiple types and locations.

Table 3

Serum catestatin levels correlation with clinical and demographic data in the OLP group (N = 51).

Variablerp *
Age (years)−0.0360.715
BMI (kg/m2)0.0070.942
REU-R score0.2650.078
REU-E score0.748<0.001
REU-U score0.770<0.001
REU total score0.781<0.001
VAS pain0.708<0.001
VAS burning0.729<0.001
Vitamin D (nmol/L)−0.0500.610

* Spearman’s correlation coefficient.

Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results

Conclusions

In this study, serum CST concentrations were increased in patients with OLP and correlated with REU total score, pain and burning. The most clinically informative finding was the higher CST concentration in erosive OLP, whereas non-erosive OLP showed CST values closer to controls. These results suggest that CST may be involved in the neuroendocrine-immune profile of OLP and may be more relevant as a marker of erosive or clinically active disease than as a general diagnostic marker for all OLP.

Confirmation in larger prospective cohorts, ideally with salivary measurements and tissue-level CST/CgA expression, is required before CST can be proposed for routine disease monitoring.

Source: 5. Conclusions
Authors’ abstract

Background/Objectives:

Oral lichen planus (OLP) is a chronic immune-mediated disease of the oral mucosa in which T-cell infiltration, epithelial injury, and stress-related neuroendocrine signaling appear to intersect. Catestatin (CST), a peptide generated from chromogranin A (CgA), modulates catecholamine release and inflammatory cell responses; however, its association with localized mucosal inflammation in OLP has not been clarified. This study aimed to compare serum CST levels between OLP patients and healthy controls and to examine their association with clinical subtype, disease severity, and vitamin D status.

Methods:

In this cross-sectional study, 51 patients with clinically and histopathologically confirmed OLP and 60 healthy controls were enrolled at the University Hospital of Split. Serum CST was quantified using ELISA. OLP severity was assessed with the REU score by a single experienced oral medicine examiner who was blinded to laboratory results, and pain and burning were recorded separately using 0 to 10 VASs.

Results:

Serum CST levels were significantly higher in OLP patients compared to healthy controls (p < 0.001). CST levels showed a strong positive correlation with the REU total score (r = 0.781, p < 0.001), as well as with VAS pain (r = 0.708, p < 0.001) and VAS burning (r = 0.729, p < 0.001). Erosive OLP exhibited significantly higher CST levels compared to the non-erosive subtype (p < 0.001). Furthermore, serum vitamin D levels were significantly lower in OLP patients (p < 0.001), with no significant correlation observed between CST and vitamin D levels.

Conclusions:

Serum CST levels were higher in OLP patients and showed close associations with REU scores and symptoms, with the strongest signal observed in erosive disease. CST may therefore contribute to the neuroendocrine-immune profile of OLP and may be useful as an adjunctive marker of clinically active or erosive disease. Larger prospective studies including salivary and tissue-based CST measurements are needed before CST can be used for routine monitoring.

Read the full paper

1. Introduction

Oral lichen planus (OLP) is a chronic immune-mediated disorder of the oral mucosa, estimated to affect roughly 0.5% to 2% of the population and observed most often in middle-aged women [1]. Clinically, OLP can appear as reticular, atrophic, erosive, plaque-like, papular or bullous lesions, with relapsing and remitting symptoms that often require long-term follow-up [2]. Its etiology has not been fully resolved, but epithelial injury is considered to be driven primarily by cytotoxic T-cell responses, together with genetic susceptibility, psychological stress, viral triggers, and systemic autoimmune influences [3].

Because OLP is classified by the World Health Organization as an oral potentially malignant disorder, surveillance remains important; published malignant transformation estimates approach 1.5% in some series [4].

Catestatin (CST) is a 21-amino-acid peptide (hCgA352-372) produced by proteolytic processing of chromogranin A (CgA), a secretory granule protein released with catecholamines from adrenal chromaffin cells and other neuroendocrine tissues [5]. Originally described as an inhibitor of nicotinic cholinergic catecholamine release, CST is now recognized as a multifunctional peptide involved in cardiovascular regulation, antimicrobial defense, metabolic control, and innate immune signaling [6,7,8]. In inflammation, CST promotes a shift from classically activated M1 macrophages toward an M2-like phenotype, decreases TNF-alpha, IL-1beta and IL-6 production, restrains leukocyte recruitment, and down-regulates endothelial adhesion molecules [9,10].

Altered circulating CST concentrations have been described in rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis and COVID-19, supporting its relevance as a systemic marker of inflammatory activity [5,6,7,8,10].

Although OLP manifests locally in the oral mucosa, its inflammatory microenvironment is influenced by systemic neuroendocrine and immune inputs. Psychological stress, a commonly reported disease modifier, activates the hypothalamic: pituitary: adrenal axis and the sympathoadrenal system, which promote catecholamine and CgA release [11,12]. Because CgA is the precursor of CST, changes in sympathoadrenal signaling could alter CST availability in parallel with OLP activity. More importantly, systemic CST can interact with pathways that are directly relevant to oral mucosal inflammation, including endothelial adhesion molecule expression, chemokine-driven leukocyte trafficking, macrophage polarization, and T-cell-dominated epithelial damage [10,13,14,15].

These mechanisms provide a biologically plausible bridge between a circulating neuroendocrine-derived peptide and the local homing and activation of lymphocytes in OLP lesions. Previous studies have examined biomarkers such as angiopoietin-2, vitamin D, immunoglobulins and salivary cortisol in OLP, but serum catestatin has not yet been specifically evaluated [16,17].

Accordingly, this study measured serum CST levels in patients with OLP and healthy controls. We also examined whether CST concentrations differ by erosive status and whether they correlate with REU-based disease activity, symptom intensity, and vitamin D concentrations.

2. Materials and Methods

2.1. Study Design and Ethical Considerations

This cross-sectional study was carried out at the Department of Oral Pathology, University Hospital of Split, between April 2023 and November 2025.

The protocol was approved by the Ethics Committee of the University Hospital of Split (No. 2181-147/01/06/LJ.Z.-23-03; 14 March 2023). The study followed the Declaration of Helsinki, and all participants received study information before providing written informed consent.

2.2. Subjects

Patients with OLP were recruited from the Department of Oral Pathology, University Hospital of Split. Participation was voluntary and anonymized, and all patients received standard clinical care. Seventy-three patients were screened; 22 were excluded because at least one inclusion or exclusion criterion was not met. Medication history was recorded at enrollment, and blood was drawn before any new OLP-directed topical or systemic treatment was initiated.

Controls were healthy volunteers attending routine dental/oral check-ups at the same institution. They had no oral mucosal lesions and no history or clinical evidence of oral inflammatory, autoimmune, potentially malignant, or malignant disease. The same exclusion criteria applied to controls and OLP patients. Current smoking was defined as any active cigarette use within the previous 30 days. Everyday alcohol consumption was recorded as daily intake of alcoholic beverages.

Inclusion criteria were age 18 to 70 years and a diagnosis of OLP.

Exclusion criteria were active malignancy; chronic renal or hepatic disease; cardiovascular disease, including arterial hypertension and use of antihypertensive medication; diabetes mellitus; rheumatologic or autoimmune disease; oral vitamin D supplementation; psychoactive substance abuse; and current topical or systemic corticosteroid therapy or other OLP-directed immunomodulatory treatment at the time of sampling.

2.3. Laboratory and Clinical Examination

All participants underwent medical history review, physical examination, anthropometric measurements, and laboratory testing. OLP diagnosis was established using clinical and histopathological criteria according to the modified World Health Organization diagnostic framework summarized in recent diagnostic recommendations [3]. Potential controls with clinical or laboratory evidence of inflammation were excluded; C-reactive protein and leukocyte count were used as laboratory screening markers. Body height and weight were measured with a calibrated medical scale with an integrated stadiometer (Seca, Birmingham, UK), and BMI was calculated as weight in kilograms divided by height in meters squared.

After a 12-h overnight fast, venous blood was collected from the cubital vein. Routine laboratory testing was performed on the day of sampling, while serum aliquots intended for CST analysis were centrifuged and stored at −80 °C until assay. All analyses followed standard laboratory procedures and were performed by the same experienced biochemist, who was blinded to group allocation.

Serum CST concentrations were measured by enzyme-linked immunosorbent assay using a commercially available kit (EK-053-27CE EIA kit, Phoenix Pharmaceuticals Inc., Burlingame, CA, USA). The manufacturer’s stated assay sensitivity was 0.05 ng/mL, with a measurement range of 0.05 to 100 ng/mL. Intra-assay and inter-assay coefficients of variation were <10% and <15%, respectively. Because no universally accepted clinical reference interval for serum CST is available for this assay, CST values were analyzed as continuous variables and compared between study groups.

Serum 25-hydroxyvitamin D [25(OH)D] was quantified using Elecsys Vitamin D (Roche Diagnostics International Ltd., Rotkreuz, Switzerland), an electrochemiluminescence immunoassay (ECLIA). Results were expressed in nmol/L, and the analytical measuring range was 7.5 to 250 nmol/L. For interpretation, vitamin D deficiency was considered <50 nmol/L, insufficiency 50 to 74.9 nmol/L, and sufficiency ≥ 75 nmol/L; however, the present analysis used continuous vitamin D values because individual category counts were not available for all analyses.

2.4. Assessment of Disease Activity

Clinical activity was graded with the Reticulation/Keratosis, Erythema, Ulceration (REU) system, a semi-quantitative clinician-reported tool that scores OLP lesions at ten intraoral sites [18]. A single experienced oral medicine specialist performed all REU assessments while blinded to CST and vitamin D results, using a standardized scoring sheet. Because only one examiner carried out the clinical grading and no repeat-scoring session was built into the protocol, formal inter-examiner and intra-examiner reliability coefficients were not available. At each site, reticulation/keratosis was scored as absent/present, erythema was scored from 0 to 3 according to surface area, and ulceration was scored from 0 to 3 according to ulcer size.

The total REU score was calculated as (R × 1) + (E × 2) + (U × 3).

Patients were classified as erosive if at least one erosive/ulcerative lesion was present at any oral site, regardless of concomitant reticular, papular, plaque-like, atrophic, or bullous changes. The non-erosive group included patients without erosive/ulcerative lesions; this group could include reticular, papular, plaque-like, or atrophic lesions.

Pain and burning were recorded separately on two distinct 0 to 10 visual analog scales (VAS). Patients were asked to rate their average spontaneous symptoms during the preceding 7 days, rather than provoked symptoms during eating, swallowing, or toothbrushing. A score of 0 represented no pain/burning, and 10 represented the worst imaginable pain/burning.

2.5. Sample Size Analysis

Sample size was estimated from pilot data obtained in 10 OLP patients and 10 matched controls. Serum CST, the primary outcome, had a mean concentration of 10.42 ± 5.75 ng/mL in the OLP group and 5.11 ± 3.11 ng/mL in controls. Assuming type I error of 0.05 and 90% power, at least 17 participants were required in each group.

2.6. Statistical Analyses

Statistical analyses were performed in MedCalc (MedCalc Software, Ostend, Belgium, version 23.5.5). Continuous variables are shown as mean ± standard deviation or median with interquartile range, depending on distribution, while categorical variables are reported as N (%). Normality was assessed with the Kolmogorov: Smirnov test. Normally distributed variables were compared using the independent-samples t-test; non-normally distributed variables were analyzed with the Mann: Whitney U test. Categorical variables were compared using the chi-square test or Fisher’s exact test when appropriate. Associations between CST and clinical variables were tested with Pearson’s or Spearman’s correlation coefficients according to distribution.

Statistical significance was set at p < 0.05.

3. Results

Overall, 111 participants were analyzed: 60 controls and 51 patients with OLP (Table 1). The groups did not differ significantly in age (p = 0.331), BMI (p = 0.479), sex (p = 0.197), smoking status (p = 0.826), or everyday alcohol consumption (p = 0.405). Unless otherwise indicated, values in parentheses represent either percentages for categorical variables or interquartile ranges for skewed continuous variables.

Reticular OLP was the most common clinical pattern (47/51, 92.2%), whereas papular, atrophic and bullous types were each recorded in one patient (2.0%) (Table 2). Because multiple lesion types and sites could coexist, erosive/ulcerative lesions were present in 35 patients (68.6%), and 16 patients (31.4%) were classified as non-erosive. The buccal mucosa was the most frequent site (92.2%), while the oral floor was least often involved (5.9%).

Serum vitamin D concentrations were lower in the OLP group than in controls (45.1 ± 17.8 vs. 53.4 ± 18.07 nmol/L, p < 0.001) (Figure 1). Based on commonly used thresholds, both mean values fall below the sufficiency cut-off of 75 nmol/L.

Median serum CST was higher in patients with OLP than in controls (13.8 [6.9 to 25.0] vs. 6.4 [5.5 to 7.6] ng/mL, p < 0.001) (Figure 2).

Within the OLP group, serum CST showed strong positive correlations with REU-E score (r = 0.748, p < 0.001), REU-U score (r = 0.770, p < 0.001), REU total score (r = 0.781, p < 0.001), VAS pain (r = 0.708, p < 0.001), and VAS burning (r = 0.729, p < 0.001) (Table 3). No other statistically significant correlations were observed.

Exploratory subtype analysis showed higher serum CST in erosive OLP than in non-erosive OLP (21.9 [11.8 to 39.4] vs. 7.7 [5.7 to 12.7] ng/mL, p < 0.001) (Figure 3). Descriptively, the non-erosive OLP median was close to the control median (7.7 vs. 6.4 ng/mL), suggesting that the overall OLP-control difference was mainly driven by the erosive subgroup.

Serum vitamin D levels were also lower in the erosive subgroup than in the non-erosive subgroup (40.4 ± 16.07 vs. 55.1 ± 17.1 nmol/L, p < 0.001) (Figure 4). The control mean (53.4 nmol/L) and the non-erosive OLP mean (55.1 nmol/L) both fell within the insufficiency range defined above.

4. Discussion

The main observation of this study was that circulating CST was higher in OLP patients than in controls and that CST was closely related to REU-based disease activity. The association was particularly evident in erosive OLP, where CST concentrations were markedly higher than in the non-erosive subgroup. These findings suggest that CST is more likely to reflect clinically active or erosive mucosal inflammation than the mere presence of OLP, and they expand the concept of a neuroendocrine-immune interface in this disease.

Increased serum CST in OLP is best interpreted within the broader neuroimmune biology of chronic mucosal inflammation. CST is generated from CgA, which is co-released with catecholamines during physiological and psychological stress [19,20]. OLP lesions are dominated by activated CD4+ and CD8+ T cells, Th1/Th17 skewing, altered Treg activity, and cytokines such as TNF-alpha, IFN-gamma, IL-6 and IL-17 [21,22,23,24]. These local processes may be linked to the systemic CST pool through stress-related CgA release, inflammation-enhanced CgA processing, and CST-mediated modulation of macrophages and leukocyte trafficking.

Experimental and clinical data indicate that CST can reduce TNF-alpha, IL-1beta and IL-6, attenuate adhesion molecule expression, and limit immune cell chemotaxis [10,15]. In this framework, higher CST could represent a compensatory counter-regulatory response to sustained mucosal inflammation. Similar increases have been reported in several inflammatory or immune-mediated conditions, including inflammatory bowel disease, rheumatoid arthritis, severe COVID-19 and cardiovascular inflammatory states [6,7,8,25], whereas reduced levels have been reported in some metabolic and hypertensive phenotypes [26,27].

Thus, CST dysregulation appears to depend on disease context, inflammatory burden and neuroendocrine activation rather than following a single direction across all disorders. To our knowledge, this is one of the first studies to report elevated serum CST in OLP.

The correlation between CST and the REU total score further supports a relationship with clinical activity. REU scoring captures reticulation/keratosis, erythema and ulceration across multiple oral sites and has been shown to correlate with pain [18,28]. As lesions become erythematous or ulcerated, epithelial barrier disruption, cytokine release and immune-cell recruitment intensify. Such conditions may enhance CgA processing and CST release from neuroendocrine and immune-cell compartments. The parallel correlations with VAS pain and VAS burning indicate that CST also tracks patient-reported symptoms, although the overall median VAS scores were low (1 for pain and 2 for burning).

These low values may reflect the inclusion of patients with limited or chronic lesions and confirm that symptom intensity should be interpreted together with objective REU scores rather than in isolation. Previous OLP biomarker studies have shown that angiopoietin-2, immunoglobulins, vitamin D and cortisol vary with disease severity [16]. Our findings add CST to this biomarker landscape and suggest a neuroendocrine dimension of OLP activity.

The higher CST concentrations observed in erosive OLP provide the clearest clinical signal in this dataset. Erosive OLP is considered a more severe phenotype, characterized by epithelial breakdown, greater symptom burden, CD8+ cytotoxic T-cell infiltration, TNF-alpha activity and basement membrane damage [29,30]. In contrast, non-erosive patterns usually show a more preserved epithelial barrier [31,32]. Therefore, the similarity between control and non-erosive CST medians in the present study is important: it suggests that CST may not be a general diagnostic marker for all OLP, but rather a marker of inflammatory escalation, ulceration or erosive activity.

This interpretation is consistent with reports that vascular and humoral biomarkers, such as angiopoietin-2 and immunoglobulins, are higher in erosive disease [16]. However, because the non-erosive subgroup was small, this finding requires confirmation in a study powered for direct comparisons among controls, non-erosive OLP and erosive OLP.

Vitamin D was lower in the overall OLP group than in controls, in line with previous studies and meta-analytic data [33,34,35,36,37]. The mean vitamin D values in both controls and the non-erosive subgroup were within the insufficiency range, which helps explain why the control mean (53.4 nmol/L) was close to the non-erosive mean (55.1 nmol/L). In contrast, the erosive subgroup had lower levels, supporting a possible link between vitamin D status and more severe mucosal disease.

Vitamin D signaling through VDR influences keratinocytes, dendritic cells, macrophages and T cells, promotes Treg differentiation and constrains Th1/Th17 responses [38,39]. Reduced vitamin D/VDR activity could therefore contribute to persistence of the inflammatory loop in OLP [35,40,41]. The lack of correlation between CST and vitamin D suggests that these biomarkers may reflect different aspects of disease biology: CST may be more closely related to neuroendocrine and inflammatory activation, whereas vitamin D reflects a VDR-centered immunoregulatory axis.

Future studies should test whether vitamin D repletion changes CST levels or whether both markers add complementary information on disease activity.

Several limitations should be acknowledged. The cross-sectional design prevents causal inference, and residual confounding cannot be excluded. The study was single-center and the sample size, particularly for the non-erosive subgroup, was modest. Importantly, OLP is a localized mucosal disease, whereas CST was measured only in serum; salivary CST, lesional CgA/CST expression, immunohistochemistry and tissue transcriptomic analyses were not performed. Clinical grading was performed by one examiner and formal inter: and intra-examiner reliability coefficients were not available, which limits assessment of scoring reproducibility.

Finally, although active corticosteroid therapy, antihypertensive treatment and vitamin D supplementation were exclusion criteria, detailed prior medication washout intervals and vitamin D category counts were not available, so residual medication: or nutritional-status confounding remains possible.

5. Conclusions

In this study, serum CST concentrations were increased in patients with OLP and correlated with REU total score, pain and burning. The most clinically informative finding was the higher CST concentration in erosive OLP, whereas non-erosive OLP showed CST values closer to controls. These results suggest that CST may be involved in the neuroendocrine-immune profile of OLP and may be more relevant as a marker of erosive or clinically active disease than as a general diagnostic marker for all OLP.

Confirmation in larger prospective cohorts, ideally with salivary measurements and tissue-level CST/CgA expression, is required before CST can be proposed for routine disease monitoring.

Acknowledgments

The authors thank ChatGPT (version 5.5), an AI-based language tool, for the enhancement of clarity and readability of selected parts of the manuscript.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

Conceptualization, M.R.K., D.M., J.B. and L.S.; methodology, D.M., J.B. and L.S.; software, E.P., L.M., J.P. and R.S.; validation, M.R.K., D.M. and L.M.; formal analysis, M.R.K., E.P., L.M., D.S.-D. and L.S.; investigation, M.R.K., E.P. and L.S.; resources, J.P., J.B. and L.S.; data curation, D.M., D.S.-D. and R.S.; writing: original draft preparation, M.R.K., D.M., E.P., L.M. and J.P.; writing: review and editing, M.R.K., D.M., E.P., L.M., J.P. and J.B.; visualization, R.S. and L.S.; supervision, J.P., D.S.-D., J.B. and L.S. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of University Hospital of Split (No. 2181-147/01/06/LJ.Z.-23-03; Date: 14 March 2023).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study. Furthermore, written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Nukaly H.Y. Halawani I.R. Alghamdi S.M.S. Alruwaili A.G. Binhezaim A. Algahamdi R.A.A. Alzahrani R.A.J. Alharamlah F.S.S. Aldumkh S.H.S. Alasqah H.M.A. Oral Lichen Planus: A Narrative Review Navigating Etiologies, Clinical Manifestations, Diagnostics, and Therapeutic Approaches J. Clin. Med. 2024 13 5280 10.3390/jcm13175280 39274493 PMC11396719
2. Akbari E. Epstein J.B. Samim F. The Importance of Recognition and Management of Oral Lichen Planus: Navigating Epidemiology, Pathogenesis, Cancer Risk, and Advances in Management Head Neck 2025 47 3172 3184 10.1002/hed.70012 40854011
3. Rotaru D.I. Păstrav O. Bolboacă S.D. Lazăr C. Chisnoiu R.M. Beyond Clinicopathological Criteria: A Practical Management Framework for Oral Lichen Planus Med. Sci. 2026 14 252 10.3390/medsci14020252 PMC13214914 42201044
4. Manchanda Y. Rathi S.K. Joshi A. Das S. Oral Lichen Planus: An Updated Review of Etiopathogenesis, Clinical Presentation, and Management Indian Dermatol. Online J. 2023 15 8 23 10.4103/idoj.idoj_652_22 38283029 PMC10810384
5. Bozic J. Kumric M. Ticinovic Kurir T. Urlic H. Martinovic D. Vilovic M. Tomasovic Mrcela N. Borovac J.A. Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective Biomedicines 2021 9 1757 10.3390/biomedicines9121757 34944578 PMC8698910
6. Luketin M. Mizdrak M. Boric-Skaro D. Martinovic D. Tokic D. Vilovic M. Supe-Domic D. Ticinovic Kurir T. Bozic J. Plasma Catestatin Levels and Advanced Glycation End Products in Patients on Hemodialysis Biomolecules 2021 11 456 10.3390/biom11030456 33803864 PMC8003327
7. Kljakovic-Gaspic T. Tokic D. Martinovic D. Kumric M. Supe-Domic D. Stojanovic Stipic S. Delic N. Vrdoljak J. Vilovic M. Ticinovic Kurir T. Prognostic Value of Catestatin in Severe COVID-19: An ICU-Based Study J. Clin. Med. 2022 11 4496 10.3390/jcm11154496 35956112 PMC9369405
8. Simac P. Perkovic D. Bozic I. Matijas M. Gugo K. Martinovic D. Bozic J. Serum catestatin levels in patients with rheumatoid arthritis Sci. Rep. 2022 12 3812 10.1038/s41598-022-07735-x 35264632 PMC8907353
9. Mahata S.K. Mahata M. Fung M.M. O’Connor D.T. Catestatin: A multifunctional peptide from chromogranin A Regul. Pept. 2010 162 33 43 10.1016/j.regpep.2010.01.006 20116404 PMC2866790
10. Muntjewerff E.M. Dunkel G. Nicolasen M.J.T. Mahata S.K. van den Bogaart G. Catestatin as a Target for Treatment of Inflammatory Diseases Front. Immunol. 2018 9 2199 10.3389/fimmu.2018.02199 30337922 PMC6180191
11. Gupta S. Jawanda M.K. Oral Lichen Planus: An Update on Etiology, Pathogenesis, Clinical Presentation, Diagnosis and Management Indian J. Dermatol. 2015 60 222 229 10.4103/0019-5154.156315 26120146 PMC4458931
12. Lavanya N. Jayanthi P. Rao U.K. Ranganathan K. Oral lichen planus: An update on pathogenesis and treatment J. Oral Maxillofac. Pathol. 2011 15 127 132 10.4103/0973-029x.84474 22529568 PMC3329692
13. El-Howati A. Thornhill M.H. Colley H.E. Murdoch C. Immune mechanisms in oral lichen planus Oral Dis. 2023 29 1400 1415 35092132 10.1111/odi.14142
14. Deng X. Wang Y. Jiang L. Li J. Chen Q. Updates on immunological mechanistic insights and targeting of the oral lichen planus microenvironment Front. Immunol. 2023 13 1023213 10.3389/fimmu.2022.1023213 36700192 PMC9870618
15. Muntjewerff E.M. Parv K. Mahata S.K. van Riessen N.K. Phillipson M. Christoffersson G. van den Bogaart G. The anti-inflammatory peptide Catestatin blocks chemotaxis J. Leukoc. Biol. 2022 112 273 278 34939227 10.1002/JLB.3CRA1220-790RR PMC9543570
16. Zhang J. Yang J. Lu W. Zang S. Tong C. Serum biomarkers in oral lichen planus: A biochemical perspective J. Med. Biochem. 2025 44 1263 1270 10.5937/jomb0-57322 41054577 PMC12497454
17. Geng L. Zhang X. Tang Y. Gu W. Identification of Potential Key Biomarkers and Immune Infiltration in Oral Lichen Planus Dis. Markers 2022 26 7386895 10.1155/2022/7386895 PMC8898126 35256894
18. Piboonniyom S.O. Treister N. Pitiphat W. Woo S.B. Scoring system for monitoring oral lichenoid lesions: A preliminary study Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2005 99 696 703 10.1016/j.tripleo.2004.07.013 15897856
19. Aung G. Niyonsaba F. Ushio H. Kajiwara N. Saito H. Ikeda S. Ogawa H. Okumura K. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines Immunology 2011 132 527 539 10.1111/j.1365-2567.2010.03395.x 21214543 PMC3075506
20. Zalewska E. Kmieć P. Sworczak K. Role of Catestatin in the Cardiovascular System and Metabolic Disorders Front. Cardiovasc. Med. 2022 9 909480 10.3389/fcvm.2022.909480 35665253 PMC9160393
21. Firth F.A. Friedlander L.T. Parachuru V.P. Kardos T.B. Seymour G.J. Rich A.M. Regulation of immune cells in oral lichen planus Arch. Dermatol. Res. 2015 307 333 339 10.1007/s00403-015-1540-8 25638329
22. Qing M. Yang D. Shang Q. Peng J. Deng J. Lu J. Li J. Dan H. Zhou Y. Xu H. CD8+ tissue-resident memory T cells induce oral lichen planus erosion via cytokine network eLife 2023 12 e83981 10.7554/elife.83981 37555396 PMC10465124
23. Maj M. Hernik K. Tyszkiewicz K. Owe-Larsson M. Sztokfisz-Ignasiak A. Malejczyk J. Janiuk I. A complex role of chromogranin A and its peptides in inflammation, autoimmunity, and infections Front. Immunol. 2025 16 1567874 10.3389/fimmu.2025.1567874 40370467 PMC12074958
24. Kumric M. Vrdoljak J. Dujic G. Supe-Domic D. Ticinovic Kurir T. Dujic Z. Bozic J. Serum Catestatin Levels Correlate with Ambulatory Blood Pressure and Indices of Arterial Stiffness in Patients with Primary Hypertension Biomolecules 2022 12 1204 10.3390/biom12091204 36139043 PMC9496451
25. Pankova O. Korzh O. Plasma catestatin levels are related to metabolic parameters in patients with essential hypertension and type 2 diabetes mellitus Heart Vessels 2024 39 144 159 37758851 10.1007/s00380-023-02318-w
26. Park H.K. Hurwitz S. Woo S.B. Oral lichen planus: REU scoring system correlates with pain Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012 114 75 82 10.1016/j.oooo.2012.02.013 22727095
27. Scavello F. Mutschler A. Hellé S. Schneider F. Chasserot-Golaz S. Strub J.M. Cianferani S. Haikel Y. Metz-Boutigue M.H. Catestatin in innate immunity and Cateslytin-derived peptides against superbugs Sci. Rep. 2021 11 15615 10.1038/s41598-021-94749-6 34341386 PMC8329280
28. Ioannidis M. van Dijk H. Muntjewerff E.M. Chirasani V.R. Warner H. van den Dool W. Grijpstra P. Bianchi F. Mahata S.K. van den Bogaart G. Inflammation Promotes Proteolytic Processing of the Prohormone Chromogranin A by Macrophages J. Endocr. Soc. 2025 9 bvaf090 10.1210/jendso/bvaf090 40458085 PMC12127132
29. Macken J.H. Senusi A. O’Toole E.A. Caley M. Rognoni E. Fortune F. Erosive lichen planus: An unmet disease burden Front. Med. 2024 11 1457667 10.3389/fmed.2024.1457667 PMC11524830 39484200
30. Jana A. Thomas J. Ghosh P. Erosive oral lichen planus inflicts higher cellular stress than reticular type J. Oral Maxillofac. Pathol. 2021 25 279 285 10.4103/0973-029x.325127 34703122 PMC8491350
31. Chen S. Wu X. Yang Y. Xu X. Xiong X. Meng W. Increased pathogenicity and pro-inflammatory capabilities of mucosal-associated invariant T cells involved in Oral Lichen Planus BMC Oral Health 2024 24 829 10.1186/s12903-024-04621-y 39039547 PMC11264365
32. Cox T. Woodhead J. Nelson B.L. Reticular Oral Lichen Planus Head Neck Pathol. 2020 14 192 194 30390195 10.1007/s12105-018-0983-6 PMC7021865
33. Saeed S. Choudhury P. Ahmad S.A. Alam T. Panigrahi R. Aziz S. Kaleem S.M. Priyadarshini S.R. Sahoo P.K. Hasan S. Vitamin D in the Treatment of Oral Lichen Planus: A Systematic Review Biomedicines 2022 10 2964 10.3390/biomedicines10112964 36428531 PMC9687323
34. García-Pola M. Rodríguez-Fonseca L. Role of Vitamin D in Oral Lichen Planus: A Case Control Study Nutrients 2024 16 2761 10.3390/nu16162761 39203896 PMC11357441
35. Motahari P. Pournaghi Azar F. Rasi A. Role of Vitamin D and Vitamin D Receptor in Oral Lichen Planus: A Systematic Review Ethiop. J. Health Sci. 2020 30 615 622 10.4314/ejhs.v30i4.17 33897222 PMC8054464
36. Shalaby R. Nawawy M.E. Selim K. Bahaa S. Refai S.E. Maksoud A.E. Sayed M.E. Essawy A. Elshaer A. ElShaer M. The role of vitamin D in amelioration of oral lichen planus and its effect on salivary and tissue IFN-γ level: A randomized clinical trial BMC Oral Health 2024 24 813 10.1186/s12903-024-04239-0 39020381 PMC11256592
37. Egido-Moreno S. Valls-Roca-Umbert J. Parra-Moreno F.J. Jané-Salas E. Blanco-Carrión A. López-López J. Association of vitamin D levels and oral lichen planus. Systematic review and meta-analysis Med. Oral Patol. Oral Cir. Bucal 2024 29 e626 e633 10.4317/medoral.26603 38907640 PMC11365062
38. Haussler M.R. Haussler C.A. Bartik L. Whitfield G.K. Hsieh J.C. Slater S. Jurutka P.W. Vitamin D receptor: Molecular signaling and actions of nutritional ligands in disease prevention Nutr. Rev. 2008 66 S98 S112 10.1111/j.1753-4887.2008.00093.x 18844852
39. Kongsbak M. Levring T.B. Geisler C. von Essen M.R. The vitamin d receptor and T cell function Front. Immunol. 2013 4 148 10.3389/fimmu.2013.00148 23785369 PMC3684798
40. Fujita H. Asahina A. Komine M. Tamaki K. The direct action of 1α,25(OH)2-vitamin D3 on purified mouse Langerhans cells Cell. Immunol. 2007 245 70 79 10.1016/j.cellimm.2007.03.007 17507001
41. Gao H. Xie T. Zhang Y. Zhao S. Su L. Chen Z. Wang G. Vitamin D and the aging skin: Insights into oxidative stress, inflammation, and barrier function Immun. Ageing 2025 22 49 10.1186/s12979-025-00536-6 41188909 PMC12584448
Figure 1

Comparison of vitamin D levels between the control and OLP group. All variables are presented as mean ± standard deviation. * student t-test.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 2

Comparison of catestatin serum levels between the control group and the OLP group. All variables are presented as median (interquartile range). * Mann: Whitney U test.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 3

Comparison of serum catestatin levels between the non-erosive and erosive OLP form groups. All variables are presented as median (interquartile range). * Mann: Whitney U test.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 4

Comparison of serum vitamin D levels between the erosive and non-erosive OLP form groups. All variables are presented as mean ± standard deviation. * Student t-test.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Comparison of sociodemographic data and habits between the study groups.

VariableStudy Sample
(N = 111)
Control Group
(N = 60)
OLP Group
(N = 51)
p
Age (years)63.0 (56.0 to 68.7)63.0 (57.0 to 66.5)65.0 (53.0 to 71.7)0.331 *
BMI (kg/m2)23.6 ± 2.423.4 ± 2.323.8 ± 2.50.479 *
Sex (N, %)
Male34 (30.6)22 (36.7)12 (23.5)0.197 †
Female77 (69.4)38 (63.3)39 (76.5)
Smoking (N, %)24 (21.6)12 (20.0)12 (23.5)0.826 *
Every day alcohol consumption (N, %)2 (1.8)0 (0)2 (3.9)0.405 *

All variables are presented as whole numbers (percentage), mean ± standard deviation or median (interquartile range). * Mann: Whitney U test. † Chi-square test or Fisher’s exact test.

Table 2

Clinical data of the OLP group.

VariableOLP Group
(N = 51)
Type of OLP * (N, %)
Reticular47 (92.2)
Papular1 (2.0)
Plaque-like10 (19.6)
Atrophic1 (2.0)
Erosive/ulcerative35 (68.6)
Bullous1 (2.0)
Exhibiting erosive/non-erosive subtypes (N, %)
Non-erosive16 (31.4)
Erosive35 (68.6)
Localization * (N, %)
Buccal mucosa47 (92.2)
Gingiva10 (19.6)
Dorsal tongue7 (13.7)
Lateral tongue6 (11.8)
Ventral tongue7 (13.7)
Palate5 (9.8)
Labial vestibulum5 (9.8)
Oral floor3 (5.9)
REU-R score2.0 (2.0 to 3.0)
REU-E score2.0 (0.0 to 5.7)
REU-U score2.0 (0 to 4.0)
REU total score6.0 (3.0 to 11.5)
VAS pain1.0 (0 to 4.0)
VAS burning2.0 (0 to 5.0)

All variables are presented as whole numbers (percentage) or median (interquartile range). * most patients had multiple types and locations.

Table 3

Serum catestatin levels correlation with clinical and demographic data in the OLP group (N = 51).

Variablerp *
Age (years)−0.0360.715
BMI (kg/m2)0.0070.942
REU-R score0.2650.078
REU-E score0.748<0.001
REU-U score0.770<0.001
REU total score0.781<0.001
VAS pain0.708<0.001
VAS burning0.729<0.001
Vitamin D (nmol/L)−0.0500.610

* Spearman’s correlation coefficient.

Publication and source details

Original title: Serum Catestatin Level as a Novel Biomarker of Oral Lichen Planus

Mia Roglic Karan; Dinko Martinovic; Ema Puizina; Lovre Martinovic; Jasna Puizina; Daniela Supe-Domic; Roko Santic; Josko Bozic; Livia Sukanec

Medical Sciences · 2026

* Correspondence: josko.bozic@mefst.hr© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:04:11.925487+00:00

DOI: 10.3390/medsci14030417 · PMC13413988